What is the sentiment of this news? Please choose an answer from {strong negative/moderately negative/mildly negative/neutral/mildly positive/moderately positive/strong positive}.

Adverum Biotechnologies Inc (NASDAQ: ADVM) announced new data from the OPTIC study of ADVM-022 for wet age-related macular degeneration (wet AMD) during the American Society of Retina Specialists 2022 Annual Meeting.  New data include best-corrected visual acuity (BCVA),.
neutral